---
layout: default
title: Calcium Gluconate
parent: 僅模型預測 (L5)
nav_order: 93
evidence_level: L5
indication_count: 0
---

# Calcium Gluconate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Calcium Gluconate: Repurposing Evaluation Incomplete — No Predictions Available

## One-Sentence Summary

Calcium Gluconate (DrugBank: DB11126) is a calcium salt preparation; however, the current Evidence Pack contains no original indication records and no TxGNN-predicted new indications. The drug is **not registered with SAHPRA**, and critical data — including mechanism of action, safety warnings, and contraindications — are absent, making a full repurposing evaluation impossible at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded in this Evidence Pack |
| Predicted New Indication | None available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model output unavailable; no supporting studies retrievable |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why Is This Prediction Reasonable?

No TxGNN repurposing prediction has been generated for Calcium Gluconate in this Evidence Pack (`predicted_indications` is empty). Without a predicted target indication, no mechanistic rationale, clinical trial evidence, or literature analysis can be presented.

Additionally, mechanism of action (MOA) data is currently unavailable for this candidate. Calcium Gluconate is broadly understood to act as a calcium supplementation agent — providing ionised calcium essential for neuromuscular function, cardiac conduction, and enzymatic processes — but this information has not been formally populated into the Evidence Pack and cannot be used to drive a repurposing hypothesis.

Until TxGNN prediction outputs are generated and MOA data is confirmed via DrugBank, no disease-linkage analysis can be completed.

---

## South Africa Market Information

Calcium Gluconate (DB11126) has **zero SAHPRA registrations** on record. The drug is listed as **not marketed** in South Africa at the time of this report (data cut-off: 2026-04-05).

There are no registration entries to tabulate. Before any repurposing pathway can be pursued, a regulatory strategy for SAHPRA submission would need to be developed from the ground up.

---

## Safety Considerations

All safety fields in this Evidence Pack are currently unresolved data gaps:

- **Key Warnings**: Not available — SAHPRA Professional Information (PI) not yet retrieved
- **Contraindications**: Not available — SAHPRA PI not yet retrieved
- **Drug–Drug Interactions**: No interactions on record (query returned 0 results)

> Please refer to the SAHPRA-approved Professional Information (PI) for safety information once registration is pursued. Report any adverse drug reactions to SAHPRA via the MedWatch equivalent reporting pathway.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Calcium Gluconate is critically incomplete: there are no TxGNN repurposing predictions, no original indication records, no safety data, and the drug holds no SAHPRA registrations. There is no evidence basis on which to proceed with any repurposing evaluation at this stage.

**To proceed, the following is needed:**

- **Re-run TxGNN pipeline**: Confirm that DB11126 is correctly represented in the knowledge graph and that prediction outputs are generated
- **Populate original indications**: Retrieve approved indications from DrugBank, WHO INN records, or international pharmacopoeias (e.g., hypocalcaemia, cardiac rescue in hyperkalaemia)
- **Resolve MOA data gap (DG002)**: Query DrugBank API for mechanism of action to enable mechanistic plausibility assessment
- **Retrieve safety data (DG001)**: Obtain SAHPRA PI or equivalent label (e.g., FDA, EMA, BNF) to populate warnings and contraindications
- **Assess SAHPRA registration pathway**: Since no local registration exists, determine whether a Section 21 authorisation or full registration application is appropriate once a repurposing indication is identified
- **Re-evaluate after data remediation**: Once TxGNN predictions and safety/MOA data are available, re-generate this report at the appropriate evidence level

---

*This report is generated for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application. YMYL disclaimer: Information herein should not be used to guide clinical decisions without review by a qualified healthcare professional.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

